1855P - Analyzing the utility of the cancer therapy satisfaction questionnaire (CTSQ)

Background

Over the last few decades, there has been a significant improvement in the survival rates of cancer patients, due to early diagnosis and advancements in treatment options. But survival benefits can only be maximized if people are able and willing to take their oncology treatment. The Cancer Therapy Satisfaction Questionnaire (CTSQ) offers a standardized way to collect information about treatment satisfaction directly from oncology patients. The objective of this study was to explore the use of the CTSQ in clinical trials and non-clinical studies.

Methods

A scoping review of scientific papers was conducted for CTSQ use using multiple electronic databases including MEDLINE, EMBASE, and Cochrane using the OVID interface. In addition, the ClinicalTrials.gov platform was also searched to identify clinical trials and non-clinical studies where CTSQ was included.

Results

Forty- two atricles and 23 clinical trials/studies were identified. The CTSQ was used in 14 different types of cancer, including solid and hematological tumors. 29.1% of research explored oral treatments, 27.3% IV treatment, and 1.8% both. In the 55 comparative studies with results the CTSQ showed a difference between treatments in 54.2% of the scientific papers. The CSTQ has been predominantly used in interventional studies to evaluate secondary outcomes of Phase III and IV clinical trials. The CTSQ has been used in more than 50 countries/languages.

Conclusions

The CTSQ is a disease-specific questionnaire to evaluate treatment satisfaction, and is being used across multiple settings, countries and studies. However, it is still only included in a small fraction of clinical trials/studies globally. As patient-focused drug development and personalized medicine/care evolves, considering not just the molecular traits of patients but also their perspectives on treatment, is likely to become more important. Although the US FDA and EMA have already expressed an interest in patient-reported efficacy and tolerability in clinical trials, treatment satisfaction may be an important addendum to understand how treatment effects in clinical trials may translate to treatment-related behaviors in routine clinical care.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

IQVIA.

Funding

IQVIA.

Disclosure

C. Navas: Financial Interests, Personal, Other, Employee: IQVIA.